CN107737103A - 一种用于治疗横纹肌肉瘤的瘤内注射液 - Google Patents
一种用于治疗横纹肌肉瘤的瘤内注射液 Download PDFInfo
- Publication number
- CN107737103A CN107737103A CN201711367399.7A CN201711367399A CN107737103A CN 107737103 A CN107737103 A CN 107737103A CN 201711367399 A CN201711367399 A CN 201711367399A CN 107737103 A CN107737103 A CN 107737103A
- Authority
- CN
- China
- Prior art keywords
- danshensu
- weight
- dimethoxy
- iodophenyl
- propane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 51
- 239000007924 injection Substances 0.000 title claims abstract description 51
- 201000009410 rhabdomyosarcoma Diseases 0.000 title claims abstract description 50
- 239000007788 liquid Substances 0.000 title claims abstract description 47
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims abstract description 72
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims abstract description 70
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims abstract description 70
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 18
- 229930195725 Mannitol Natural products 0.000 claims abstract description 18
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 18
- 239000000594 mannitol Substances 0.000 claims abstract description 18
- 235000010355 mannitol Nutrition 0.000 claims abstract description 18
- 239000001632 sodium acetate Substances 0.000 claims abstract description 18
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000008215 water for injection Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- YLXORIUDTVJQRM-UHFFFAOYSA-N 1-iodo-1-phenylpropan-2-amine Chemical compound CC(N)C(I)C1=CC=CC=C1 YLXORIUDTVJQRM-UHFFFAOYSA-N 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 9
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 7
- 239000003708 ampul Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims 6
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 150000001412 amines Chemical class 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- RDCXZZYPYHQEDV-UHFFFAOYSA-N 1-iodo-2,5-dimethoxy-4-propylbenzene Chemical compound CCCC1=CC(OC)=C(I)C=C1OC RDCXZZYPYHQEDV-UHFFFAOYSA-N 0.000 abstract 3
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 abstract 1
- -1 dimethoxy, 4 iodophenyl propane Chemical compound 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 208000016686 tic disease Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- QVFDMWGKHUFODK-UHFFFAOYSA-N 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine;hydrochloride Chemical compound Cl.COC1=CC(CC(C)N)=C(OC)C=C1I QVFDMWGKHUFODK-UHFFFAOYSA-N 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 2
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 208000017708 myomatous neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 210000002948 striated muscle cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- BGMZUEKZENQUJY-UHFFFAOYSA-N 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine Chemical compound COC1=CC(CC(C)N)=C(OC)C=C1I BGMZUEKZENQUJY-UHFFFAOYSA-N 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711367399.7A CN107737103B (zh) | 2017-12-18 | 2017-12-18 | 一种用于治疗横纹肌肉瘤的瘤内注射液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711367399.7A CN107737103B (zh) | 2017-12-18 | 2017-12-18 | 一种用于治疗横纹肌肉瘤的瘤内注射液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107737103A true CN107737103A (zh) | 2018-02-27 |
CN107737103B CN107737103B (zh) | 2018-09-04 |
Family
ID=61240090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711367399.7A Active CN107737103B (zh) | 2017-12-18 | 2017-12-18 | 一种用于治疗横纹肌肉瘤的瘤内注射液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107737103B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111419837A (zh) * | 2020-05-07 | 2020-07-17 | 南京赛尔健生物技术有限公司 | 12α-甲氧基-吉玛烷-三烯-12,6α-缩醛的抗人横纹肌肉瘤用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102212008A (zh) * | 2010-04-09 | 2011-10-12 | 暨南大学 | 丹参素川芎嗪衍生物及其制备方法和应用 |
-
2017
- 2017-12-18 CN CN201711367399.7A patent/CN107737103B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102212008A (zh) * | 2010-04-09 | 2011-10-12 | 暨南大学 | 丹参素川芎嗪衍生物及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
YONG ZHANG ET AL.: "Tanshinones:sources, pharmacokinetics and anti-cancer activities", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
曹乃龙等: "骶髓5-HT2A受体对于正常大鼠排尿的影响", 《临床泌尿外科杂志》 * |
舒菁菁等: "丹参素药理作用及机制的研究进展", 《药学实践杂志》 * |
陈达灿等: "《皮肤性病科专病中医临床诊治 第2版》", 31 October 2000 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111419837A (zh) * | 2020-05-07 | 2020-07-17 | 南京赛尔健生物技术有限公司 | 12α-甲氧基-吉玛烷-三烯-12,6α-缩醛的抗人横纹肌肉瘤用途 |
CN111419837B (zh) * | 2020-05-07 | 2023-03-03 | 北正赛欧(北京)生物科技有限公司 | 12α-甲氧基-吉玛烷-三烯-12,6α-缩醛的抗人横纹肌肉瘤用途 |
Also Published As
Publication number | Publication date |
---|---|
CN107737103B (zh) | 2018-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109718208B (zh) | 多糖修饰的纳米硒复合物在恶性腹水治疗药物中的应用 | |
CN101612400A (zh) | 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用 | |
CN111840291B (zh) | 一种在肿瘤治疗中具有增效作用的化合物的应用 | |
CN102670578A (zh) | 原苏木素b作为制备抗膀胱癌灌注液的应用 | |
CN107737103B (zh) | 一种用于治疗横纹肌肉瘤的瘤内注射液 | |
CN103263416A (zh) | 一种吡啶胺化合物在制备适于口服给药的治疗肺癌的药物中的应用 | |
CN105476996A (zh) | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 | |
CN111214475B (zh) | 一种抗双重打击淋巴瘤的联合用药物组合物及其应用 | |
CN102920729A (zh) | 低聚甘露糖醛酸或其药用盐在制备防治白细胞减少症药物中的应用 | |
CN109432086A (zh) | 青蒿素或其衍生物与egfr-tki靶向药物的组合物的应用 | |
CN110664807A (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
CN1839855A (zh) | 人参皂苷f1的医药用途 | |
CN107441076B (zh) | 一种治疗癌症的联合用药物 | |
CN108503676A (zh) | 用于癌症治疗的果糖类似物及其组合物 | |
CN113440519A (zh) | 霉酚酸及其衍生物在制备靶向治疗癌症药物中的应用 | |
CN102526731A (zh) | 一种含有牛蒡苷元的药物组合物 | |
CN108853114B (zh) | 硝呋莫司在制备治疗癌症衍生的脑转移瘤的药物中的应用 | |
CN112076216A (zh) | 三氧化二砷在治疗胃肠道间质瘤中的应用 | |
CN105193810B (zh) | 5‑氟尿嘧啶组合物及其在制备抗肿瘤注射剂中的应用 | |
CN1267093C (zh) | 黄芩甙元在制备抗肿瘤药物中的用途 | |
CN103483187A (zh) | 4-乙氧基-2-羟基-6-甲基苯甲酸及其药用组合物和应用 | |
CN101797242A (zh) | 半胱胺在制备治疗癌症的药物中的应用 | |
CN101530408B (zh) | 抗肿瘤药物组合物及其应用 | |
CN101721471B (zh) | 含利血生的升白药物 | |
CN107661324B (zh) | 普罗帕酮在制备治疗食管癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: Chengtun town health center, yuncheng county, Heze City, Shandong Province Patentee after: Zhang Xin Address before: Weifang City, Shandong Province health Street 262700 Shouguang City, Shouguang City People's Hospital No. 1233 tumor three Patentee before: Zhang Xin |
|
CP02 | Change in the address of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240328 Address after: Room A202, 2nd Floor, Building 2, No. 9 Yike Road, Life Science Park, Changping District, Beijing, 102200 Patentee after: Microevolution (Beijing) Medical Technology Co.,Ltd. Country or region after: China Address before: 274716 health center of chengtun Town, yuncheng county, Heze City, Shandong Province Patentee before: Zhang Xin Country or region before: China |
|
TR01 | Transfer of patent right |